1. Home
  2. RCUS vs NMFC Comparison

RCUS vs NMFC Comparison

Compare RCUS & NMFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCUS
  • NMFC
  • Stock Information
  • Founded
  • RCUS 2015
  • NMFC 2010
  • Country
  • RCUS United States
  • NMFC United States
  • Employees
  • RCUS N/A
  • NMFC N/A
  • Industry
  • RCUS Biotechnology: Pharmaceutical Preparations
  • NMFC Finance/Investors Services
  • Sector
  • RCUS Health Care
  • NMFC Finance
  • Exchange
  • RCUS Nasdaq
  • NMFC Nasdaq
  • Market Cap
  • RCUS 1.2B
  • NMFC 1.2B
  • IPO Year
  • RCUS 2018
  • NMFC 2011
  • Fundamental
  • Price
  • RCUS $12.03
  • NMFC $9.69
  • Analyst Decision
  • RCUS Buy
  • NMFC Hold
  • Analyst Count
  • RCUS 8
  • NMFC 3
  • Target Price
  • RCUS $20.71
  • NMFC $10.33
  • AVG Volume (30 Days)
  • RCUS 711.9K
  • NMFC 506.9K
  • Earning Date
  • RCUS 11-05-2025
  • NMFC 10-29-2025
  • Dividend Yield
  • RCUS N/A
  • NMFC 13.09%
  • EPS Growth
  • RCUS N/A
  • NMFC N/A
  • EPS
  • RCUS N/A
  • NMFC 0.77
  • Revenue
  • RCUS $262,000,000.00
  • NMFC $355,675,000.00
  • Revenue This Year
  • RCUS N/A
  • NMFC N/A
  • Revenue Next Year
  • RCUS N/A
  • NMFC N/A
  • P/E Ratio
  • RCUS N/A
  • NMFC $12.74
  • Revenue Growth
  • RCUS 6.07
  • NMFC N/A
  • 52 Week Low
  • RCUS $6.50
  • NMFC $8.84
  • 52 Week High
  • RCUS $18.98
  • NMFC $12.15
  • Technical
  • Relative Strength Index (RSI)
  • RCUS 66.27
  • NMFC 24.73
  • Support Level
  • RCUS $11.30
  • NMFC $9.59
  • Resistance Level
  • RCUS $12.05
  • NMFC $10.70
  • Average True Range (ATR)
  • RCUS 0.58
  • NMFC 0.16
  • MACD
  • RCUS 0.02
  • NMFC -0.09
  • Stochastic Oscillator
  • RCUS 81.30
  • NMFC 8.93

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

About NMFC New Mountain Finance Corporation

New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.

Share on Social Networks: